Patch Test Skin Irritation/Sensitization of Cetaphil Daily Facial Moisturizer SPF 50
Subject Repeat Insult Patch Test Skin Irritation/Sensitization Evaluation (Occlusive Patch)
1 other identifier
interventional
100
1 country
1
Brief Summary
Determine if Cetaphil Daily Facial Moisturizer SPF 50 proves to be a contact sensitizer or irritant in certain individuals.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2013
CompletedFirst Submitted
Initial submission to the registry
June 24, 2013
CompletedFirst Posted
Study publicly available on registry
June 27, 2013
CompletedJuly 29, 2022
June 1, 2013
1 month
June 24, 2013
July 28, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Area of erythema and edema measured
9 consecutive 24hr exposures for every Monday, Wednesday, and Friday for 3 consecutive weeks
3 consecutive weeks
Study Arms (1)
Cetaphil Daily Facial Moisturizer SPF50
EXPERIMENTALAll subjects receive Cetaphil Daily Facial Moisturizer SPF 50
Interventions
Other: Cetaphil Daily Advance Ultra Hydrating Lotion 0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
Eligibility Criteria
You may qualify if:
- Not currently under a doctor's care
- Free of dermatological or systemic disorder which would interfere with the results
- Free of any acute or chronic disease
- Will complete a preliminary medical history form and are in general good health
- Can read, understand, and sign informed consent
You may not qualify if:
- Under 18 years old
- Currently under doctor's care
- Currently taking any medication
- History of acute or chronic disease
- Diagnosed with chronic skin allergies
- Pregnant or lactating
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Galderma R&Dlead
Study Sites (1)
AMA Laboratories
New City, New York, 10956, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Mayya Tastene, MD
AMA Laboratories
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 24, 2013
First Posted
June 27, 2013
Study Start
December 1, 2012
Primary Completion
January 1, 2013
Last Updated
July 29, 2022
Record last verified: 2013-06